---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056427"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:31:39.775381+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q3 net product revenue $24.5M (+41% YoY); appoints Hugh O'Dowd CEO

## Summary
- CEO Robert Finizio to become Vice Chair; President Hugh O'Dowd becomes CEO effective on or before Dec 31, 2021.
- Q3 net product revenue $24.5M, up 41% YoY; ANNOVERA TRx 8,351 (+62.7% YoY).
- Net loss $47.4M ($0.11/sh) vs $32.6M ($0.12/sh) in Q3 2020; includes $7.3M severance.
- Cost savings plan to cut SG&A by $40M in 2022; additional ~$20M annualized from vitaCare divestiture.
- Manufacturing issues: ANNOVERA batch failures; supplemental NDA PDUFA date Dec 12, 2021; revenue covenant risk.

## SEC filing metadata
- accession: 0001564590-21-056427
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/txmd-8k_20211111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056427
- JSON: https://secwatch.observer/filing/0001564590-21-056427.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056427.txt

## Key facts
- Executive change
  Hugh O'Dowd was appointed as Director at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Director
  source text: Mr. O’Dowd will also be appointed to the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm
- Executive change
  Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Mr. Hugh O’Dowd, the Company’s current President, will succeed Mr. Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, as the Company’s Chief Executive Officer effective on or before December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm
- Executive change
  Robert G. Finizio was appointed as Vice Chair of the Board of Directors at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Vice Chair of the Board of Directors
  source text: Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.